Live Analyst Rating Changes 34759 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sam Slutsky
LIFE

Sam Slutsky

LifeSci Capital
Wall Street Analyst
★★☆☆☆
#2444
on 13Foresight · ranked by our own returns
44%
Success Rate
+2.5%
Average Return
42 of 96 calls profitable · +20.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 44% of Sam Slutsky's ratings turned a profit when each position was held for 1 year — averaging +2.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

240 Buy 17 Hold 0 Sell
Sam's Stock Coverage 24 ratings · 2026-09-26
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ORKA
Oruka Therapeutics
 Sep 23, 2026 BUY Strong Buy
+58.8% avg upside
16 analysts
$175.00
107.14% Upside
 -6.1% ·
IMVT
Immunovant
 Sep 23, 2026 BUY Strong Buy
+20.7% avg upside
24 analysts
$53.00
59.22% Upside
 -1.3% ·
ABVX
Abivax SA Sponsored ADR
 Sep 22, 2026 BUY Strong Buy
+45.2% avg upside
16 analysts
$168.00
84.54% Upside
 -5.5% ·
PYXS
Pyxis Oncology
 Sep 22, 2026 BUY Strong Buy
+184.4% avg upside
15 analysts
$8.00
179.76% Upside
 · ·
CLDX
Celldex
 Sep 20, 2026 BUY Strong Buy
+35.6% avg upside
28 analysts
$56.00
80.16% Upside
 -17.9% ·
OLMA
Olema Pharmaceuticals
 Sep 19, 2026 BUY Strong Buy
+302.7% avg upside
16 analysts
$16.00
82.78% Upside
 -8.3% ·
DMRA
Damora Therapeutics
 Sep 18, 2026 BUY Strong Buy
+46.9% avg upside
20 analysts
$45.00
117.82% Upside
 +0.0% ·
COGT
Cogent Biosciences
 Sep 15, 2026 BUY Strong Buy
+20.6% avg upside
26 analysts
$55.00
70.23% Upside
 -5.2% ·
AVBP
ArriVent BioPharma, Inc.
 Sep 14, 2026 BUY Strong Buy
+51.6% avg upside
15 analysts
$43.00
51.13% Upside
 +6.1% ·
IMUX
Immunic
 Sep 11, 2026 BUY Strong Buy
+314.5% avg upside
22 analysts
$56.00
499.33% Upside
 -7.0% ·
SYRE
Spyre Therapeutics
 Sep 08, 2026 BUY Strong Buy
+8.9% avg upside
23 analysts
$116.00
35.36% Upside
 -2.9% ·
ATTO
Attovia Therapeutics, Inc.
 Sep 05, 2026 BUY Strong Buy
+123.5% avg upside
4 analysts
$45.00
153.14% Upside
 -10.0% ·
TCRX
TScan Therapeutics
 Sep 02, 2026 HOLD Buy
+2153.3% avg upside
12 analysts
 — -10.6% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Aug 27, 2026 BUY Strong Buy
+87.7% avg upside
11 analysts
$22.52
99.20% Upside
 +17.7% ·
QNCX
Quince Therapeutics
 Aug 19, 2026 BUY Buy
+511.3% avg upside
18 analysts
$98.00
216.04% Upside
 -14.7% ·
OBX
Obsidian Therapeutics
 Aug 18, 2026 BUY Strong Buy
+34.1% avg upside
11 analysts
$43.00
234.30% Upside
 -35.5% ·
ELVN
Enliven Therapeutics
 Aug 08, 2026 BUY Strong Buy
+33.7% avg upside
16 analysts
$70.00
56.45% Upside
 -22.4% ·
CGON
CG Oncology, Inc.
 Aug 07, 2026 BUY Strong Buy
+27.3% avg upside
17 analysts
$108.00
60.82% Upside
 -8.4% ·
ALXO
ALX Oncology Holdings
 Aug 06, 2026 HOLD Strong Buy
+1269.1% avg upside
11 analysts
 — -35.8% ·
IFRX
InflaRx
 Aug 06, 2026 BUY Strong Buy
+365.1% avg upside
12 analysts
$5.00
164.63% Upside
 +21.5% ·
OKUR
OnKure Therapeutics
 Aug 05, 2026 BUY Strong Buy
+661.7% avg upside
13 analysts
$16.00
451.82% Upside
 -30.3% ·
PVLA
Palvella Therapeutics
 Aug 05, 2026 BUY Strong Buy
+20.4% avg upside
27 analysts
$236.00
70.72% Upside
 -3.5% ·
DBVT
DBV Technologies SA - American
 Jul 17, 2026 BUY Strong Buy
+107.5% avg upside
15 analysts
$45.00
289.28% Upside
 -21.4% ·
GYRE
Gyre Therapeutics
 Aug 09, 2023 HOLD Strong Buy
+183.0% avg upside
15 analysts
 — +103.9% ·
🔒 19 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sam Slutsky — Frequently Asked Questions
How accurate are Sam Slutsky's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Sam's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, or +20.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Sam ranked on 13Foresight?
Sam Slutsky is currently ranked #2444 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sam cover?
Sam most recently has ratings on ORKA, IMVT, ABVX, PYXS, CLDX, OLMA, DMRA, COGT, AVBP, IMUX, SYRE, ATTO and 12 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.